Norstella and Citeline Announce Complete Merger

November 1, 2022

Norstella, a biotech that provides end-to-end services for therapeutic development has merged with Citeline, a leader in pharma intelligence. The acquisition brings the value of Norstella up to $5 billion, ranking among the largest in the industry. Norstella will use Citeline’s range of services and assets to help improve the company’s drug development support services.

According to Norstella’s CEO Mike Gallup, “We believe that patient access starts with identifying unmet needs and doesn’t end until a patient has a therapy in hand. As the industry moves toward highly targeted therapies focused on smaller patient populations, our clients need solutions that provide actionable answers to critical business questions to help bring drugs to market quicker—ultimately helping patients receive treatment sooner”

To read more, click here.

(Source: Panalgo, November 1st, 2022)

Share This Story!